Denali Therapeutics Inc. (DNLI) Can’t Be More Safe. Trades Significantly Higher

March 14, 2018 - By Henry Gaston

The stock of Denali Therapeutics Inc. (NASDAQ:DNLI) is a huge mover today! The stock increased 8.80% or $1.77 during the last trading session, reaching $21.89. About 367,066 shares traded or 11.57% up from the average. Denali Therapeutics Inc. (NASDAQ:DNLI) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 9 months positive chart setup for the $1.97 billion company. It was reported on Mar, 14 by We have $23.64 PT which if reached, will make NASDAQ:DNLI worth $157.68M more.

More notable recent Denali Therapeutics Inc. (NASDAQ:DNLI) news were published by: which released: “Denali Therapeutics Announces First Clinical Trial Application, Key …” on August 25, 2016, also with their article: “Takeda and Denali team up in neurodegenerative diseases” published on January 05, 2018, published: “Drug maker led by Genenexers, and targeting Alzheimer’s, Parkinson’s and ALS …” on November 14, 2017. More interesting news about Denali Therapeutics Inc. (NASDAQ:DNLI) were released by: and their article: “Denali Therapeutics: An IPO Trap Or Something More?” published on January 06, 2018 as well as‘s news article titled: “Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership …” with publication date: February 08, 2018.

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company has market cap of $1.97 billion. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It currently has negative earnings. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.